TBPH — Theravance Biopharma Income Statement
0.000.00%
Last trade - 00:00
- $429.63m
- $327.20m
- $57.42m
- 31
- 25
- 48
- 26
2019 December 31st | R2020 December 31st | R2021 December 31st | 2022 December 31st | 2023 December 31st | |
---|---|---|---|---|---|
Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
Standards: | USG | USG | USG | USG | USG |
Status: | Final | Final | Final | Final | Final |
Revenue | |||||
Total Revenue | 73.4 | 71.9 | 55.3 | 51.3 | 57.4 |
Cost of Revenue | |||||
Gross Profit | 73.4 | — | — | — | — |
Selling / General / Administrative Expenses | |||||
Research And Development | |||||
Unusual Expense / Income | |||||
Total Operating Expenses | 325 | 369 | 313 | 146 | 113 |
Operating Profit | -252 | -298 | -258 | -95 | -56 |
Total Net Non Operating Interest Income / Expense | |||||
Other Net Non Operating Costs | |||||
Net Income Before Taxes | -242 | -303 | -265 | -92.8 | -49.3 |
Provision for Income Taxes | |||||
Net Income After Taxes | -236 | -295 | -265 | -92.8 | -55.2 |
Net Income Before Extraordinary Items | |||||
Extraordinary Items | |||||
Net Income | -236 | -278 | -199 | 872 | -55.2 |
Income Available to Common Shareholders Excluding Extraordinary Items | |||||
Income Available to Common Shareholders Including Extraordinary Items | |||||
Diluted Net Income | -236 | -278 | -199 | 872 | -55.2 |
Diluted Weighted Average Shares | |||||
Basic EPS Including Extraordinary Items | |||||
Diluted EPS Including Extraordinary Items | |||||
Diluted EPS Excluding Extraordinary Items | |||||
Normalised Income Before Taxes | |||||
Normalised Income After Taxes | |||||
Normalised Income Available to Common Shareholders | |||||
Diluted Normalised EPS | -4.25 | -4.73 | -3.63 | -1.12 | -0.966 |